–   Discoveries support next phase of collaboration with AbbVie –     Cambridge, Mass (Business Wire)  – Synlogic™ has completed the first phase of its ongoing collaboration with AbbVie. During this first discovery phase of the collaboration Synlogic has identified Synthetic...

CAMBRIDGE, Mass. –( BUSINESS WIRE )–Synlogic announced today that its President and Chief Executive Officer, Jose Carlos Gutierrez-Ramos, Ph.D., will speak at the Jefferies 2017 Global Healthcare Conference on Friday, June 9th at 1:30 p.m. in New York City....

On May 16, 2017, Synlogic and Mirna Therapeutics held a conference call to discuss the proposed merger as well as Synlogic’s platform and pipeline assets. The replay can be accessed through the below link and conference ID. Webcast Link:  http://edge.media-server.com/m/p/zutpri3c Conference ID...

– Transaction Expected to Advance Synlogic’s Innovative Platform for the Discovery and Development of Novel Synthetic Biotic™ Medicines – – Synlogic Closes $42 Million of Series C Preferred Stock Financing by Leading Biotechnology Investors – – Combined Company Well-Capitalized with Approximately...

Synlogic and Mirna Therapeutics will host a conference call to discuss the proposed transaction as well as Synlogic’s platform and pipeline assets on  May 16, 2017 at 8:30 AM ET . The live webcast can be accessed through the information below....

Cambridge, Mass (BUSINESS WIRE).  March 22 nd , 2017.  Synlogic™ Inc. today announced that the company will present preclinical data on two rare metabolic disease programs from its Synthetic Biotics™ platform at the American College of Medical Genetics and Genomics Annual Meeting from...

Experienced biotechnology leader, Sam Truex, joins Synlogic’s leadership team CAMBRIDGE, Mass., December 15, 2016 – CAMBRIDGE, Mass. – Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its proprietary synthetic biology and microbiome platform, today announced...

First Live  E. Coli  Nissle Bacterium Modified to Assimilate Ammonia Potential Treatment of Urea Cycle Disorders and Other Forms of Hyperammonemia CAMBRIDGE, Mass.–( BUSINESS WIRE )–Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its...

Company Appoints Seasoned Biotech Executives to Lead Finance, Clinical, Translational and Manufacturing Functions September 12, 2016 08:00 AM Eastern Daylight Time CAMBRIDGE, Mass.–( BUSINESS WIRE )–Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its...

The Company Has Developed The First Live  E. Coli  Nissle Bacterium Modified To Assimilate Ammonia For The Potential Treatment Of Urea Cycle Disorders CAMBRIDGE, Mass.–( BUSINESS WIRE )–Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its...

CAMBRIDGE, Mass., – March 23, 2016 –  Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its proprietary synthetic biology and microbiome platform, today announced the expansion of its Board of Directors with the appointment of Mr....

Additional funding to accelerate the two lead Urea Cycle Disorder and Phenylketonuria pipeline programs to the clinic and expand the Synthetic Biotics platform CAMBRIDGE, Mass., – February 17, 2016 –  Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its...